DeepPsy AG
DeepPsy offers precision psychiatry by leveraging proprietary medical software to analyze electrophysiological data (EEG and ECG) for patients. Their technology extracts biomarkers that predict treatment response to various psychiatric therapies including SSRIs, SNRIs, rTMS, ketamine, and ECT. This patient-centered approach aims to reduce trial-and-error in treatment selection, leading to faster patient recovery and improved outcomes. DeepPsy operates in Switzerland and the UK, providing reports that are covered by insurance in Switzerland. They also offer services to pharmaceutical companies for patient stratification in clinical trials and provide academic licenses for their software. The company emphasizes evidence-based practices, certified quality (ISO 13485), and the use of AI and biobanks for continuous improvement.
DeepPsy AG
DeepPsy offers precision psychiatry by leveraging proprietary medical software to analyze electrophysiological data (EEG and ECG) for patients. Their technology extracts biomarkers that predict treatment response to various psychiatric therapies including SSRIs, SNRIs, rTMS, ketamine, and ECT. This patient-centered approach aims to reduce trial-and-error in treatment selection, leading to faster patient recovery and improved outcomes. DeepPsy operates in Switzerland and the UK, providing reports that are covered by insurance in Switzerland. They also offer services to pharmaceutical companies for patient stratification in clinical trials and provide academic licenses for their software. The company emphasizes evidence-based practices, certified quality (ISO 13485), and the use of AI and biobanks for continuous improvement.